EMD Serono wins accelerated FDA approval for targeted NSCLC drug Feb. 4, 2021 By Michael Fitzhugh No Comments Just weeks after seeing one late-stage candidate hit a wall in a subtype of non-small-cell lung cancer (NSCLC), Merck KGaA's EMD Serono has won accelerated approval from the FDA for another important NSCLC therapy, Tepmetko (tepotinib).Read More